Literature DB >> 17304533

Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma.

Amy C Baruch1, Huamin Wang, Gregg A Staerkel, Douglas B Evans, Rosa Frances Hwang, Savitri Krishnamurthy.   

Abstract

Mesothelin is a potential marker of pancreatic adenocarcinoma that was recently identified by serial analysis of gene expression. We evaluated the sensitivity and specificity of mesothelin as a marker of pancreatic adenocarcinoma on destained Papanicolaou (Pap) smears and unstained cellblocks from 28 patients using a monoclonal antibody to mesothelin. Intensity and proportion of staining was semiquantitatively graded on a scale of 1-3, and as 0%, 1 to <10%, 10-50%, or >50%. Positive staining for mesothelin was seen in 64% of the direct smears and in 36% of cell block sections. Focal positivity for mesothelin was noted in benign pancreatic tissue in one of 10 cases. Staining was most often focal (<50% of cells) in both direct smears and cell block sections. The overall sensitivity and specificity of mesothelin as a marker for pancreatic adenocarcinoma were 68% and 90%, respectively. Sensitivity was higher in Pap smears than in cell block sections (64% versus 36%). The presence of occasional mesothelin expression in benign tissue, its very focal expression in malignant tissue may limit the utility of mesothelin as a marker of pancreatic adenocarcinomas in fine-needle aspiration (FNA) specimens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17304533     DOI: 10.1002/dc.20594

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  8 in total

1.  Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis.

Authors:  Qianqian Wang; Tao Wang; Zhu Wang; Hong Zheng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.

Authors:  Sabrina C Sopha; Purva Gopal; Nipun B Merchant; Frank L Revetta; David V Gold; Kay Washington; Chanjuan Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

Review 3.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

4.  Diagnostic value of mesothelinin pancreatic cancer: a meta-analysis.

Authors:  Lin Zhu; Yiling Liu; Guangyuan Chen
Journal:  Int J Clin Exp Med       Date:  2014-11-15

5.  Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy.

Authors:  Elizabeth FitzSullivan; Roland L Bassett; Henry M Kuerer; Elizabeth A Mittendorf; Min Yi; Kelly K Hunt; Gildy V Babiera; Abigail S Caudle; Dalliah M Black; Isabelle Bedrosian; Chantal Reyna; Mediget Teshome; Funda Meric-Bernstam; Rosa Hwang
Journal:  Ann Surg Oncol       Date:  2016-10-03       Impact factor: 5.344

Review 6.  Biological approaches to therapy of pancreatic cancer.

Authors:  Han Hsi Wong; Nicholas R Lemoine
Journal:  Pancreatology       Date:  2008-08-25       Impact factor: 3.996

Review 7.  A quarter century of EUS-FNA: Progress, milestones, and future directions.

Authors:  Irina Mihaela Cazacu; Adriana Alexandra Luzuriaga Chavez; Adrian Saftoiu; Peter Vilmann; Manoop S Bhutani
Journal:  Endosc Ultrasound       Date:  2018 May-Jun       Impact factor: 5.628

8.  Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel.

Authors:  Asif Ali; Victoria Brown; Simon Denley; Nigel B Jamieson; Jennifer P Morton; Colin Nixon; Janet S Graham; Owen J Sansom; C Ross Carter; Colin J McKay; Fraser R Duthie; Karin A Oien
Journal:  BMC Clin Pathol       Date:  2014-07-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.